Detail akcie Kuros Bioscienc N online

Business Summary: Kuros Biosciences AG is a Switzerland-based biotechnology company engaged in the discovery, development and commercialization of biopharmaceutical products known as Immunodrugs. Immunodrugs are therapeutic vaccines intended for treating and preventing common chronic diseases, such as hypertension, nicotine addiction, allergic diseases, asthma, malignant melanoma and Alzheimer's disease. They are designed to instruct the patient's immune system to produce desired therapeutic antibody or T cell responses that modulate chronic disease processes. The Company has built a pipeline of different Immunodrug candidates, of which five are in clinical development. Its Immunodrug candidates are developed both in-house and together with Novartis, Pfizer and Pfizer Animal Health, among others. The Company has two subsidiaries: a wholly-owned Proteome Therapeutics GmbH and minority owned BioSupport AG.
Financial Summary: BRIEF: For the six months ended 30 June 2024, Kuros Biosciences AG revenues increased from SF12.9M to SF31.8M. Net loss decreased 96% to SF211K. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Finance income increase from SF689K to SF2.1M (income), Finance expense decrease of 58% to SF434K (expense).